{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"18"},{"groupId":"OG002","value":"0"}]}],"title":"Blood and lymphatic system disorders"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"}]}],"title":"Cardiac disorders"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"}]}],"title":"Eye disorders"},{"categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"0"}]}],"title":"Gastrointestinal disorders"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"1"}]}],"title":"General disorders and administration site conditions"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"1"}]}],"title":"Infections and infestations"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}],"title":"Injury, poisoning and procedural complications"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"}]}],"title":"Investigations"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"}]}],"title":"Musculoskeletal and connective tissue disorders"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"}]}],"title":"Nervous system disorders"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"1"}]}],"title":"Respiratory, thoracic and mediastinal disorders"},{"categories":[{"measurements":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"}]}],"title":"Skin and subcutaneous tissue disorders"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}],"title":"Vascular disorders"}],"denoms":[{"counts":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"25"},{"groupId":"OG002","value":"25"}],"units":"Participants"}],"description":"We will define categories for toxicity events and for each category we will determine the highest grade experienced by each patient. We will then report the number of patients with each grade in each category.","groups":[{"description":"Patients with SMN treated with up to 2 courses of CPX-351 who developed grade 2 toxicity","id":"OG000","title":"Grade 2 Toxicity"},{"description":"Patients with SMN treated with up to 2 courses of CPX-351 who developed grade 3 toxicity","id":"OG001","title":"Grade 3 Toxicity"},{"description":"Patients with SMN treated with up to 2 courses of CPX-351 who developed grade 4 toxicity","id":"OG002","title":"Grade 4 Toxicity"}],"paramType":"NUMBER","populationDescription":"All 25 eligible patients.","reportingStatus":"POSTED","timeFrame":"Adverse events will be monitored from the time of first study intervention or treatment until 30 days after off-therapy.","title":"Toxicity Profile of Patients With SMN Treated With One or Two Courses of CPX-351","type":"SECONDARY","unitOfMeasure":"participants"}